

PERSONAL INFORMATION

Full name: Roberta Fazio
Date of birth: 01 October 1993
Place of birth: Messina (Italy)
Email address: roberta.fazio@istitutotumori.mi.it

CURRENT POSITION

Title: **Medical Oncologist**
Department: Medical Oncology, Gastrointestinal Unit
Institution: **IRCSS Istituto Nazionale dei Tumori**
Address: Via Giacomo Venezian, 1, 20133, Milan - Italy
Start date: 01.12.2024

PREVIOUS WORKING EXPERIENCES

Period: From 04.11.2019 to 11.11.2024
Position: **Medical Oncology Resident**
Institution: **IRCSS Humanitas Research Hospital**
Address: Via Alessandro Manzoni, 56, 20089, Rozzano (Milan) - Italy

Period: From 01.02.2023 to 31.01.2024
Position: **Medical Research Fellow**
Institution: **Institut Jules Bordet, Department of Digestive Oncology**
Address: Rue Meylemeersch, 1070, Anderlecht (Bruxelles) - Belgium

PROFESSIONAL REGISTRATIONS

Period: From 01.03.2019
Council: **College of Physicians, Palermo (Italy)**
Type of registration: Full registration with a licence to practise
Registration number: 16309

QUALIFICATIONS

Qualification: **Medical Oncologist**
Year: 2024
Institution: IRCCS Humanitas Research Hospital, Rozzano (Milan)- Italy

Qualification: **Diploma in Medicine and Surgery**
Year: 2018
Institution: University of Palermo - Italy

EDUCATION

Period: From November 2019 to November 2024
Institution: **Humanitas Research Hospital - Italy**
Degree/Qualification: **Medical Oncology Resident**
Mark: 70 cum laude/70

Period: From September 2016 to February 2017
Institution: **Coimbra University - Portugal**
Degree/Qualification: **Visiting Scholar (Erasmus+ fellowship)**
Mark: Not applicable

Period: From 2012 to 2018
Institution: **University of Palermo - Italy**
Degree/Qualification: **Bachelor of Medicine, Bachelor of Surgery**
Mark: 110 cum laude/110

Period: From 2007 to 2012
Institution: **State Classical High School “Giuseppe Garibaldi”, Palermo –Italy**
Degree/Qualification: **Classical High-School Diploma**
Mark: 100 cum laude/100

PROFESSIONAL TASKS

First language: Italian (native speaker)
Other languages: English (fluent written/spoken)
Portuguese (basic communication skills)
French (basic communication skills)

Technical knowledge: Excellent knowledge of Microsoft Office Suite (Word, Excel, PowerPoint).
Excellent knowledge of Microsoft Windows
Excellent knowledge of use of software for clinical activities.

PUBLICATIONS

- Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study. Pizzocaro A, Colombo P, Vena W, et al. Endocrine. 2021 Aug;73(2):255-260.
- Advances in drug treatment for mesothelioma. Zucali PA, ...Fazio R et al. Expert Opinion on Pharmacotherapy, 2022; 23:8, 929-946.
- Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID- regional centers of Lombardy, Italy. Lazzeri M, Duga S, Azzolini E, et al. Minerva Urol Nephrol; 2022; 74:77-84.
- How To Develop an Adolescent and Young Adult Program in an Adult Cancer Center: the Humanitas Research Hospital Experience. Fazio R, Grimaudo MS, Laffi A et al. CTOS Annual Meeting 2022 (poster presentation, P117).
- Should Regorafenib Be Prescribed As A Continuous Schedule At Least In Gastrointestinal Stromal Tumors (Gist)? Grimaudo MS, Fazio R, D’Orazio F, et al. CTOS Annual Meeting 2022 (poster presentation, P08).
- Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule. Grimaudo MS, Laffi A, Gennaro N, Fazio R, D’Orazio F, et al. Front. Oncol. 2023; 13:119012.

- Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy Perrino M, Cordua N, De Vincenzo F, Borea F,...Fazio R, et al. *Cancers* 2023,15,5574.
- Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer. Assaf I, Fimereli D, Anthoine G, Fazio R, Daprà V, et al. *Cancers* 2023, 15, 5823
- Neoadjuvant chemotherapy for resectable colon cancer in the era of precision oncology: a step forward or a step back? Audisio A, Fazio R, Hendlitz A, Sclafani F. *Curr. Opin. Oncol.* 2023; 35(4):p 315-317
- Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand? Daprà V, Airolidi M, Bartolini M, Fazio R, Mondello G, et al. *Int. J. Mol. Sci.* 2023, 24, 12159.
- Neoadjuvant chemotherapy for early-stage colon cancer. Audisio A, Fazio R, Daprà V, Assaf I, et al. *Cancer Treatment Reviews.* 2024;123, 102676.
- Highlights from the ESMO Annual Meeting 2023 e EORTC GI Tract Group picks from the colorectal and anal cancer track. Fazio R, Arnold D, Folprecht G, et al. *ESMO Gastrointestinal Oncology*, 2024.
- Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs. Perrino M, Voulaz E, Balin S, ...Fazio R...and Mavilio D. *Front. Immunol.* 2024 15:1288045.
- Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? Stucchi E, Bartolini M, Airolidi M, Fazio R, et al. *Expert Opin Pharmacother.* 2024 Apr 3:1-12.
- Clinical Outcome of Colorectal Cancer Patients with Concomitant Hypertension: A Systematic Review and Meta-Analysis. Sur D, Coroama CI, Audisio A, Fazio R et al. *J. Pers. Med.* 2024, 14, 520.
- Current trends of clinical trials for older patients with cancer: A systematic review ASCO 2024 poster presentation (Care Delivery/Models of Care session). Fazio R et al., *JCO* (2024) 42, 1621-1621
- State of the art of gastrointestinal (GI) cancer trials for older patients (pts): A systematic review (SR) Poster presentation at ESMO GI 2024. Fazio R et al. *Annals of Oncology*, 2024, Volume 35, S201 - S202.
- Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers. Fazio R, Audisio A, Daprà V, et al. *Cancer Treat Rev.* 2024 Jul;128:102752.
- First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy? Airolidi M, Bartolini M, Fazio R, et al. *Curr Oncol Rep.* 2024 Nov;26(11):1489-1501.